Venetoclax, the first-in-class drug of BCL-2 inhibitors, selectively triggers apoptosis in cells dependent on BCL-2 for survival and has demonstrated favorable outcomes in patients with a diverse spectrum of hematologic neoplasms, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma (MM) (1–5). The gene discussed is BCL2; the disease is plasma cell myeloma.